CTSO stock icon

Cytosorbents Corp
CTSO

$0.77
6.14%
 

About: CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Employees: 186

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.78% less ownership

Funds ownership: 34.36% [Q4 2023] → 33.58% (-0.78%) [Q1 2024]

6% less funds holding

Funds holding: 52 [Q4 2023] → 49 (-3) [Q1 2024]

16% less capital invested

Capital invested by funds: $19.9M [Q4 2023] → $16.6M (-$3.26M) [Q1 2024]

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$1
30%
upside
Avg. target
$1.50
95%
upside
High target
$3
291%
upside

4 analyst ratings

positive
25%
neutral
75%
negative
0%
B. Riley Securities
Yuan Zhi
291%upside
$3
Buy
Reiterated
15 May 2024
HC Wainwright & Co.
Sean Lee
30%upside
$1
Neutral
Reiterated
7 May 2024
HC Wainwright & Co.
Sean Lee
30%upside
$1
Neutral
Reiterated
15 Mar 2024
HC Wainwright & Co.
Sean Lee
30%upside
$1
Neutral
Downgraded
29 Dec 2023

Financial journalist opinion